UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1088 LIVER TRANSPLANTATION FOR EARLY HEPATOCELLULAR CARCINOMA AT MINORITY- VS. NON-MINORITY-SERVING HOSPITALS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1499-S-1500

2023

Volltextzugriff (PDF)

1095 DISPARITIES IN GUIDELINE-COMPLIANT CARE AND SURVIVAL FOR EARLY-ONSET VERSUS AVERAGE-ONSET BILIARY TRACT CANCERS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1502-S-1503

2023

Volltextzugriff (PDF)

292 NEOADJUVANT RADIOTHERAPY IS ASSOCIATED WITH IMPROVED PATHOLOGIC OUTCOMES AND SURVIVAL IN RESECTED STAGE II-III PANCREATIC ADENOCARCINOMA TREATED WITH MULTI-AGENT NEOADJUVANT CHEMOTHERAPY IN THE MODERN ERA

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-876-S-876

2021

Volltextzugriff (PDF)

302 REASSESSING THE ROLE OF OPERATIVE INTERVENTION IN ELDERLY PATIENTS WITH NON-FUNCTIONAL PANCREATIC NEUROENDOCRINE TUMORS

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-879-S-880

2021

Volltextzugriff (PDF)

5-fluorouracil enhances the anti-tumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers

Cancer research (Chicago, Ill.), 2020-09, Vol.80 (21), p.4815-4827

2020

Volltextzugriff (PDF)

5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA -Mutant Colorectal Cancers

Cancer research (Chicago, Ill.), 2020-11, Vol.80 (21), p.4815-4827

2020

Volltextzugriff (PDF)

782 TransCon TLR7/8 agonist induces sustained local and systemic immune activation in patients with solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A879-A879

2023

Volltextzugriff (PDF)

Abstract 3187: Depleting cells expressing fibroblast activation protein disrupts tumor-promoting desmoplasia

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3187-3187

2015

Volltextzugriff (PDF)

Abstract 5176: Chemotherapy alters the natural history of metastatic progression

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.5176-5176

2015

Volltextzugriff (PDF)

Abstract 5535: SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5535-5535

2020

Volltextzugriff (PDF)

Abstract A10: Soluble CD25 and C-reactive protein predict overall survival in melanoma patients receiving anti-CD40 monoclonal antibody CP-870,893 (αCD40) and anti-CTLA4 monoclonal antibody tremelimumab

Cancer immunology research, 2015-10, Vol.3 (10_Supplement), p.A10-A10

2015

Volltextzugriff (PDF)

Abstract A38: Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (αCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic melanoma

Cancer immunology research, 2015-10, Vol.3 (10_Supplement), p.A38-A38

2015

Volltextzugriff (PDF)

Abstract CT005: T cell inflammation in the tumor microenvironment after agonist CD40 antibody: Clinical and translational results of a neoadjuvant clinical trial

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT005-CT005

2021

Volltextzugriff (PDF)

Abstract CT078: Phase 1 study of SGN-EGFRd2 in solid tumors (SGNEGFRd2-001)

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT078-CT078

2024

Volltextzugriff (PDF)

Abstract CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT137-CT137

2015

Volltextzugriff (PDF)

Abstract CT246: Phase 1b/2 study of giloralimab in combination with modified FOLFIRINOX with or without budigalimab in patients with untreated metastatic pancreatic cancer

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT246-CT246

2022

Volltextzugriff (PDF)

Abstract CT252: transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT252-CT252

2022

Volltextzugriff (PDF)

Abstract LB-294: Targeting glutamine addiction of PIK3CA mutant colorectal cancers: From preclinical models to clinical trials

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.LB-294-LB-294

2019

Volltextzugriff (PDF)

Abstract PR08: Pulling out all the stops: Exploiting macropinocytosis inhibition for the treatment of pancreatic cancer

Cancer research (Chicago, Ill.), 2015-07, Vol.75 (13_Supplement), p.PR08-PR08

2015

Volltextzugriff (PDF)

Abstract PR09: Targeting glutamine addiction of PIK3CA mutant colorectal cancers: From preclinical models to clinical trials

Molecular cancer research, 2020-10, Vol.18 (10_Supplement), p.PR09-PR09

2020

Volltextzugriff (PDF)

Abstract PR14: Lineage labeling elucidates the natural history of metastatic colonization

Cancer research (Chicago, Ill.), 2013-10, Vol.73 (19_Supplement), p.PR14-PR14

2013

Volltextzugriff (PDF)

Adding Base Excision Repair Inhibitor TRC102 to standard Pemetrexed-Platinum-Radiation in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of a phase I trial

Clinical cancer research, 2022-02, Vol.28 (4), p.646-652

2022

Volltextzugriff (PDF)

Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed-Platinum-Radiation in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer: Results of a Phase I Trial

Clinical cancer research, 2022-02, Vol.28 (4), p.646-652

2022

Volltextzugriff (PDF)

Addressing Sleep Impairment in Treatment Guidelines for PTSD

The American journal of psychiatry, 2013-09, Vol.170 (9), p.1059-1059

2013

Volltextzugriff (PDF)

Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Journal of clinical oncology, 2023-04, Vol.41 (11), p.2007-2019

2023

Volltextzugriff (PDF)

1 – 25 von 142

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(131)
Mit Volltextzugriff
(127)

Publikationsform

Sprache

Englisch
(142)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(37)
Cancer Research
(14)
Clinical Cancer Research
(7)
Gastroenterology
(6)
Cancer Immunology Research
(5)
Hpb
(4)
Surgery
(4)
Annals Of Surgical Oncology
(2)
Boletín Del Museo Nacional De Historia Natural
(2)
Cancers
(2)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

1088 LIVER TRANSPLANTATION FOR EARLY HEPATOCELLULAR CARCINOMA AT MINORITY- VS. NON-MINORITY-SERVING HOSPITALS

1095 DISPARITIES IN GUIDELINE-COMPLIANT CARE AND SURVIVAL FOR EARLY-ONSET VERSUS AVERAGE-ONSET BILIARY TRACT CANCERS

292 NEOADJUVANT RADIOTHERAPY IS ASSOCIATED WITH IMPROVED PATHOLOGIC OUTCOMES AND SURVIVAL IN RESECTED STAGE II-III PANCREATIC ADENOCARCINOMA TREATED WITH MULTI-AGENT NEOADJUVANT CHEMOTHERAPY IN THE MODERN ERA

302 REASSESSING THE ROLE OF OPERATIVE INTERVENTION IN ELDERLY PATIENTS WITH NON-FUNCTIONAL PANCREATIC NEUROENDOCRINE TUMORS

5-fluorouracil enhances the anti-tumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers

5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA -Mutant Colorectal Cancers

782 TransCon TLR7/8 agonist induces sustained local and systemic immune activation in patients with solid tumors

Abstract 3187: Depleting cells expressing fibroblast activation protein disrupts tumor-promoting desmoplasia

Abstract 5176: Chemotherapy alters the natural history of metastatic progression

Abstract 5535: SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors

Abstract A10: Soluble CD25 and C-reactive protein predict overall survival in melanoma patients receiving anti-CD40 monoclonal antibody CP-870,893 (αCD40) and anti-CTLA4 monoclonal antibody tremelimumab

Abstract A38: Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (αCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic melanoma

Abstract CT005: T cell inflammation in the tumor microenvironment after agonist CD40 antibody: Clinical and translational results of a neoadjuvant clinical trial

Abstract CT078: Phase 1 study of SGN-EGFRd2 in solid tumors (SGNEGFRd2-001)

Abstract CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma

Abstract CT246: Phase 1b/2 study of giloralimab in combination with modified FOLFIRINOX with or without budigalimab in patients with untreated metastatic pancreatic cancer

Abstract CT252: transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors

Abstract LB-294: Targeting glutamine addiction of PIK3CA mutant colorectal cancers: From preclinical models to clinical trials

Abstract PR08: Pulling out all the stops: Exploiting macropinocytosis inhibition for the treatment of pancreatic cancer

Abstract PR09: Targeting glutamine addiction of PIK3CA mutant colorectal cancers: From preclinical models to clinical trials

Abstract PR14: Lineage labeling elucidates the natural history of metastatic colonization

Adding Base Excision Repair Inhibitor TRC102 to standard Pemetrexed-Platinum-Radiation in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of a phase I trial

Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed-Platinum-Radiation in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer: Results of a Phase I Trial

Addressing Sleep Impairment in Treatment Guidelines for PTSD

Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Suchergebnisse filtern